EchoGo® Heart Failure vs ElucidVivo A.3
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A focuses on detecting Heart Failure with preserved Ejection Fraction (HFpEF) using echocardiograms, providing rapid insights for diagnosis. Tool B, on the other hand, specializes in the quantitative analysis of arterial plaque composition and stability from CT angiography to aid in atherosclerosis patient stratification. While both are AI-powered cardiology tools, they address different cardiovascular conditions and utilize distinct imaging modalities, making them complementary rather than directly competitive.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
EchoGou00ae Heart Failure (Tool A) is designed to analyze routine echocardiograms to detect Heart Failure with preserved Ejection Fraction (HFpEF). ElucidVivo A.3 (Tool B) provides quantitative analysis of arterial plaque composition and stability from CT angiography to assist in atherosclerosis patient stratification and optimize treatment decisions.
EchoGou00ae Heart Failure (Tool A) analyzes routine echocardiogram video clips. ElucidVivo A.3 (Tool B) performs its quantitative analysis on CT angiography images.
EchoGou00ae Heart Failure (Tool A) delivers AI-powered HFpEF detection insights within 20 minutes and automated structured reports. ElucidVivo A.3 (Tool B) objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications, visualizes lesion-level plaque composition, offers 3D vessel visualization, and derives fractional flow reserve (FFRct).
EchoGou00ae Heart Failure (Tool A) offers seamless integration with existing workflows and IT stacks, utilizing a DICOM workflow for report delivery to PACS. ElucidVivo A.3 (Tool B) is a software application that integrates with PACS/EMR, though specific deployment details are not explicitly detailed beyond being a software application.
EchoGou00ae Heart Failure (Tool A) is reimbursable via CPT code 0932T for outpatient analysis, with a national Medicare average of $316 per analysis, and is covered by Medicare and select commercial insurers. For ElucidVivo A.3 (Tool B), pricing information requires contacting the company, and specific reimbursement codes are not provided.
EchoGou00ae Heart Failure (Tool A) is clinically validated with 90% sensitivity and 86% specificity for HFpEF, trained on over 10 years of outcome data. ElucidVivo A.3 (Tool B) provides quantitative analysis of plaque characteristics validated against ground-truth histology and derives FFRct based on vessel wall vasodilative capacity.